Summary
EnterohemorrhagicEscherichia coli (EHEC) causes a variety of clinical conditions, the most important being hemorrhagic colitis and hemolytic uremic syndrome. A curative therapy of EHEC diseases is not yet feasible. This study investigates the antibody reactivity of Lactobin®, a standardized immunoglobulin (Ig) preparation, obtained from the colostra of non-immunized cows. Three different batches of Lactobin® exhibited equally high titers of specific antibodies againstShiga-like toxins (SLTs, verocytotoxins) and EHEC hemolysin (EHEC-Hly) produced byE. coli O157. In addition, Lactobin® blocked the cytotoxic effect of SLT-I and SLT-II on Vero cell monolayers and inhibited the cytolytic effects of EHEC-Hly on human erythrocytes. Since Lactobin® contains high levels of antibodies and neutralizing activity against important virulence factors of EHEC O157, this drug has potential use in the treatment of diarrhea and the prevention of EHEC-associated hemolytic uremic syndrome.
Zusammenfassung
EnterohämorrhagischeEscherichia coli (EHEC) verursachen eine Reihe klinischer Zustandsbilder. Von besonderer Bedeutung sind die hämorrhagische Enteritis und das hämolytisch-urämische Syndrom (HUS). Eine Kausaltherapie der durch EHEC verursachten Infektionskrankheiten ist bisher nicht verfügbar. In der vorliegenden Untersuchung wird über die Antikörperreaktivität von Lactobin®, einem standardisiert hergestellten Immunglobulin (Ig)-Präparat aus Kolostren nicht immunisierter Kühe berichtet. Drei unterschiedliche Produktionschargen zeigten gleichmäßig hohe Titer spezifischer Antikörper gegenShiga-like-Toxine (SLTs, Verotoxine) und EHEC-Hämolysin (EHEC-Hly) ausE. coli O157. Lactobin® blockierte den zytotoxischen Effekt von SLT-I und SLT-II auf Verozellen (Monolayers) und hemmte die zytolytischen Effekte von EHEC-Hly auf menschliche Erythrozyten. Da Lactobin® hohe Antikörpertiter und neutralisierende Eigenschaften gegen wichtige Virulenzfaktoren von EHEC O157 enthält, besitzt dieses Arzneimittel möglicherweise ein pharmakodynamisches Potential für die Behandlung von EHEC-bedingten Durchfallerkrankungen bzw. für die Prophylaxe eines assoziierten HUS.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Tarr, P. I. Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin. Infect. Dis. 20 (1995) 1–10.
Siegler, R. L., Milligan, M. K., Burningham, T. H., Christofferson, R. D., Chang, S. Y., Jorde, L. B. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J. Pediatr. 118 (1991) 195–200.
Boyce, T. G., Swerdlow, D. L., Griffin, P. M. Escherichia coli O157:H7 and the hemolytic uremic syndrome. N. Engl. J. Med. 333 (1995) 364–368.
Schmidt, H., Beutin, L., Karch, H. Molecular analysis of the plasmid-encoded hemolysin ofEscherichia coli O157:H7 strain EDL 933. Infect. Immun. 63 (1995) 1055–1061.
Bauer, M. E., Welch, R. A. Characterization of an RTX toxin from enterohemorrhagicEscherichia coli O157:H7. Infect. Immun. 64 (1996) 167–175.
Chapman, P. A., Wright, D. J., Siddons, C. A. A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producingEscherichia coli O157 from bovine faeces. J. Med. Microbiol. 40 (1994) 424–427.
Montenegro, M. A., Bulte, M., Trumpf, T., Aleksic, S., Reuter, G., Bulling, E., Helmuth, R. Detection and characterization of fecal verotoxin-producingEscherichia coli from healthy cattle. J. Clin. Microbiol. 28 (1990) 1417–1421.
Wieler, L. H., Bauerfeind, R., Baljer, G. Characterization ofShiga-like toxin producingEscherichia coli (SLTEC) isolated from calves with and without diarrhoea. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 276 (1992) 243–253.
Pirro, F., Wieler, L. H., Failing, K., Bauerfeind, R., Baljer, G. Neutralizing antibodies againstShiga-like toxins fromEscherichia coli in colostra and sera of cattle. Vet. Microbiol. 43 (1995) 131–141.
Brussow, H., Hilpert, H., Walther, I., Sidoti, J., Mietens, C., Bachmann, P. Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. J. Clin. Microbiol. 25 (1987) 982–986.
Tacket, C. O., Losonsky, G., Link, H., Hoang, Y., Guesry, P., Hilpert, H., Levine, M. M. Protection by milk immunoglobulin concentrate against oral challange with enterotoxigenicEscherichia coli. N. Engl. J. Med. 318 (1988) 1240–1243.
Nord, J., Ma, P., DiJohn, D., Tzipori, S., Tacket, C. O. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS 4 (1990) 581–584.
Gunzer, F., Karch, H. Expression of A and B subunits ofShiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology. J. Clin. Microbiol. 31 (1993) 2604–2610.
Stephan, W., Dichtelmüller, H., Lissner, R. Antibodies from colostrum in oral immunotherapy. J. Clin. Chem. Clin. Biochem. 28 (1990) 19–23.
Schmidt, H., Montag, M., Bockemühl, J., Heesemann, J., Karch, H. Shiga-like toxin II-related cytotoxins inCitrobacter freundii strains from humans and beef samples. Infect. Immun. 61 (1993) 534–543.
Gentry, M. K., Dalrymple, J. M. Quantitative microtiter cytotoxicity assay forShigella toxin. J. Clin. Microbiol. 12 (1980) 361–366.
Walterspiel, J. N., Ashkenazi, S., Morrow, A. L., Cleary, T. G. Effect of subinhibitory concentrations of antibiotics on extracellularShiga-like toxin I. Infection 20 (1992) 25–29.
Proulx, F., Turgeon, J. P., Delage, G., Lafleur, L., Chicoine, L. Randomized, controlled trial of antibiotic therapy forEscherichia coli O157:H7 enteritis. J. Pediatr. 121 (1992) 299–303.
Carter, A. O., Borczyk, A. A., Carlson, J. A., Harvey, B., Hockin, J. C., Karmali, M. A., Krishnan, C., Korn, D. A., Lior, H. A severe outbreak ofEscherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N. Engl. J. Med. 317 (1987) 1496–1500.
Pavia, A. T., Nichols, C. R., Green, D. P., Tauxe, R. V., Mottice, S., Greene, K. D., Wells, J. G., Siegler, R. L., Brewer, E. D., Hannon, D., Blake, P. A. Hemolyticuremic syndrome during an outbreak ofEscherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J. Pediatr. 116 (1990) 544–551.
Ostroff, S. M., Kobayashi, J. M., Lewis, J. H. Infections withEscherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 262 (1989) 355–359.
Cimolai, N., Carter, J. E., Morrison, B. J., Anderson, J. D. Risk factors for the progression ofEscherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J. Pediatr. 116 (1990) 589–592. [Published erratum appeared in J. Pediatr. 116 (1990) 1008.]
Armstrong, G. D., Fodor, E., Vanmaele, R. Investigation ofShiga-like toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 164 (1991) 1160–1167.
Armstrong, G. D., Rowe, P. C., Goodyer, P., Orrbine, E., Klassen, T. P., Wells, G., MacKenzie, A., Lior, H., Blanchard, C., Auclair, F., Thompson, B., Rafter, D. J., McLaine, P. N. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J. Infect. Dis. 171 (1995) 1042–1045.
MacLeod, D. L., Gyles, C. L., Wilcock, B. P. Reproduction of edema disease of wine with purifiedShiga-like toxin-II variant. Vet. Pathol. 28 (1991) 66–73.
Richardson, S. E., Rotman, T. A., Jay, V., Smith, C. R., Becker, L. E., Petric, M., Olivieri, N. F., Karmali, M. A. Experimental verocytotoxemia in rabbits. Infect. Immun. 60 (1992) 4154–4167.
Sandvig, K., Olsnes, S., Brown, J. E., Petersen, O. W., van Deurs, B. Endocytosis from coated pits ofShiga toxin: a glycolipid-binding protein fromShigella dysenteriae 1. J. Cell Biol. 108 (1989) 1331–1343.
Gunzer, F., Böhler, O., Henkel, B., Schwarzkopf, A., Schmidt, H., Karch, H., Lissner, R. Capability of commercial immunoglobulin preparations to react with and neutralizeShiga-like toxin II. In:Karmali, M. A., Goglio, A. G. (eds.): Recent advances in verocytotoxin-producingEscherichia coli infections. Elsevier Science, Amsterdam 1994, pp. 349–352.
Bitzan, M., Klemt, M., Steffens, R., Müller-Wiefel, D. E. Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls. Infection 21 (1993) 140–145.
Scotland, S. M., Rowe, B., Smith, H. R., Willshaw, G. A., Gross, R. J. Vero cytotoxin-producing strains ofEscherichia coli from children with haemolytic uraemic syndrome and their detection by specific DNA probes. J. Med. Microbiol. 25 (1988) 237–243.
Bitzan, M., Ludwig, K., Klemt, M., König, H., Büren, J., Müller-Wiefel, D. E. The role ofEscherichia coli O157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a central European, multicentre study. Epidemiol. Infect. 110 (1993) 183–196.
Ostroff, S. M., Tarr, P. I., Neill, M. A., Lewis, J. H., Hargrett Bean, N., Kobayashi, J. M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae inEscherichia coli O157:H7 infections. J. Infect. Dis. 160 (1989) 994–998.
Cohen, A., Madrid Marina, V., Estrov, Z., Freedman, M. H., Lingwood, C. A., Dosch, H. M. Expression of glycolipid receptors toShiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int. Immunol. 2 (1990) 1–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lissner, R., Schmidt, H. & Karch, H. A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity againstShiga-like toxins and EHEC-hemolysin ofEscherichia coli O157:H7. Infection 24, 378–383 (1996). https://doi.org/10.1007/BF01716084
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01716084